Literature DB >> 23018234

The NAD metabolome--a key determinant of cancer cell biology.

Alberto Chiarugi1, Christian Dölle, Roberta Felici, Mathias Ziegler.   

Abstract

NAD is a vital molecule in all organisms. It is a key component of both energy and signal transduction--processes that undergo crucial changes in cancer cells. NAD(+)-dependent signalling pathways are many and varied, and they regulate fundamental events such as transcription, DNA repair, cell cycle progression, apoptosis and metabolism. Many of these processes have been linked to cancer development. Given that NAD(+)-dependent signalling reactions involve the degradation of the molecule, permanent nucleotide resynthesis through different biosynthetic pathways is crucial for incessant cancer cell proliferation. This necessity supports the targeting of NAD metabolism as a new therapeutic concept for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23018234     DOI: 10.1038/nrc3340

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  133 in total

Review 1.  Function and metabolism of sirtuin metabolite O-acetyl-ADP-ribose.

Authors:  Lei Tong; John M Denu
Journal:  Biochim Biophys Acta       Date:  2010-02-20

Review 2.  The clinical development of inhibitors of poly(ADP-ribose) polymerase.

Authors:  H Calvert; A Azzariti
Journal:  Ann Oncol       Date:  2011-01       Impact factor: 32.976

3.  Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases.

Authors:  William C Hallows; Susan Lee; John M Denu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-21       Impact factor: 11.205

Review 4.  PARP inhibition: PARP1 and beyond.

Authors:  Michèle Rouleau; Anand Patel; Michael J Hendzel; Scott H Kaufmann; Guy G Poirier
Journal:  Nat Rev Cancer       Date:  2010-03-04       Impact factor: 60.716

Review 5.  Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.

Authors:  Martina Lukasova; Julien Hanson; Sorin Tunaru; Stefan Offermanns
Journal:  Trends Pharmacol Sci       Date:  2011-09-22       Impact factor: 14.819

6.  Cyclic ADP-ribose as an endogenous regulator of the non-skeletal type ryanodine receptor Ca2+ channel.

Authors:  L G Mészáros; J Bak; A Chu
Journal:  Nature       Date:  1993-07-01       Impact factor: 49.962

7.  Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.

Authors:  Anne von Heideman; Ake Berglund; Rolf Larsson; Peter Nygren
Journal:  Cancer Chemother Pharmacol       Date:  2009-09-30       Impact factor: 3.333

8.  DBC1 is a negative regulator of SIRT1.

Authors:  Ja-Eun Kim; Junjie Chen; Zhenkun Lou
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

9.  Increased 5-phospho-alpha-D-ribose-1-diphosphate synthetase (ribosephosphate pyrophosphokinase, EC 2.7.6.1) activity in rat hepatomas.

Authors:  J M Baló-Banga; G Weber
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

Review 10.  Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

Authors:  Gianluca Papeo; Barbara Forte; Paolo Orsini; Claudia Perrera; Helena Posteri; Alessandra Scolaro; Alessia Montagnoli
Journal:  Expert Opin Ther Pat       Date:  2009-10       Impact factor: 6.674

View more
  226 in total

Review 1.  Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.

Authors:  Josiah Gerdts; Daniel W Summers; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  Neuron       Date:  2016-02-03       Impact factor: 17.173

2.  Characterization of NAD salvage pathways and their role in virulence in Streptococcus pneumoniae.

Authors:  Michael D L Johnson; Haley Echlin; Tina H Dao; Jason W Rosch
Journal:  Microbiology       Date:  2015-08-25       Impact factor: 2.777

3.  Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Authors:  Claudia C S Chini; Anatilde M Gonzalez Guerrico; Veronica Nin; Juliana Camacho-Pereira; Carlos Escande; Maria Thereza Barbosa; Eduardo N Chini
Journal:  Clin Cancer Res       Date:  2013-09-11       Impact factor: 12.531

4.  RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1α-mediated mitochondrial oxidative phosphorylation and glycolysis.

Authors:  W Chen; Q Wang; L Bai; W Chen; X Wang; C S Tellez; S Leng; M T Padilla; T Nyunoya; S A Belinsky; Y Lin
Journal:  Cell Death Differ       Date:  2014-02-28       Impact factor: 15.828

5.  Generation, Release, and Uptake of the NAD Precursor Nicotinic Acid Riboside by Human Cells.

Authors:  Veronika Kulikova; Konstantin Shabalin; Kirill Nerinovski; Christian Dölle; Marc Niere; Alexander Yakimov; Philip Redpath; Mikhail Khodorkovskiy; Marie E Migaud; Mathias Ziegler; Andrey Nikiforov
Journal:  J Biol Chem       Date:  2015-09-18       Impact factor: 5.157

Review 6.  Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming.

Authors:  Lidia de Bari; Anna Atlante
Journal:  Cell Mol Life Sci       Date:  2018-05-04       Impact factor: 9.261

7.  Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.

Authors:  Ivyna Pau Ni Bong; Ching Ching Ng; Shaik Kamal Fakiruddin; Moon Nian Lim; Zubaidah Zakaria
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

8.  CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools.

Authors:  Jeffrey P Chmielewski; Sarah C Bowlby; Frances B Wheeler; Lihong Shi; Guangchao Sui; Amanda L Davis; Timothy D Howard; Ralph B D'Agostino; Lance D Miller; S Joseph Sirintrapun; Scott D Cramer; Steven J Kridel
Journal:  Mol Cancer Res       Date:  2018-08-03       Impact factor: 5.852

9.  BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.

Authors:  Da Li; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Xiu-Xia Wang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.

Authors:  Da Li; Fang-Fang Bi; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Qing Yang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.